Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO

Cue Biopharma Inc. (NASDAQ:CUE) is one of the 10 Unstoppable Stocks That Could Double Your Money.

Cue Biopharma Inc. (NASDAQ:CUE) is one of the unstoppable stocks that could double your money. On March 27, Cue Biopharma announced a leadership transition, appointing Lucinda Warren as interim president and chief executive officer. Warren, who joined the company in 2024 and most recently served as chief financial & business officer, succeeds Usman Azam. Dr. Azam stepped down from his executive roles and the board of directors as of March 26.

Warren brings over 30 years of global pharmaceutical and biotechnology experience to the position, including a significant tenure at Johnson & Johnson, where she led business development for neuroscience and the Japan region. During her time at Cue Biopharma, she has been instrumental in executing several high-value strategic transactions. These include the return of worldwide rights for CUE-401, a collaboration with Boehringer Ingelheim for CUE-501, and a license agreement with ImmunoScape for solid tumor cell therapies.

Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO

The board of directors expressed full support for Warren as she leads the company through this transition period. The company’s immediate priority remains the advancement of its lead candidate, CUE-401, into clinical trials by H2 2026. Management continues to focus on developing its novel class of therapeutic biologics for autoimmune and inflammatory diseases while pursuing creative deals to enhance shareholder value.

Cue Biopharma Inc. (NASDAQ:CUE) is a biopharma company that deals in injectable therapeutics to engage & modulate targeted, disease-relevant T cells. The company develops a pipeline of preclinical & clinical immunotherapy candidates, such as lead products CUE-401 for immune tolerance and CUE-501 for autoimmune diseases, alongside CUE-101 and CUE-102 for various cancers.

While we acknowledge the risk and potential of CUE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CUE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.